Research, development, production: We continue to grow!
We recently celebrated our fourth company birthday – time to look back and at the same time look forward with excitement:
For us, the past year was characterized by optimization and further development. This is evidenced by the successful certification of our company according to ISO 9001 or the further development of our lung models for the investigation of lung infection diseases such as Covid-19.
Our organ-on-chip platform is very well received in the market. We are experiencing great interest in our organ models from pharmaceutical companies and are already working with renowned partners. The special features of our Dynamic42-BioChips, such as the integration of immune cells, as well as the expertise in blood vessel biology, contribute significantly to this.
We are very pleased about the great interest in our technology. For us as a young company, this is a sign that we are on the right track: We are growing, and we continue to grow!
Team Dynamic42 2021
Support for our team
Our team also continues to grow. Dr. Thi Ngoc Mai Hoang and Dr. Astrid Enkelmann have been supporting us since the beginning of this year. Mai expands our research team. In her previous work, she studied the interaction of pathogens with human immune cells. With her expertise, she will support us in the development of the lung and lung infection models in the Dynamic42-BioChip. Astrid will also support us in the laboratory. With her, we have gained an expert on issues related to the progressive improvement, reduction and elimination of animal testing.
More space for research
Already last year we planned with growth for our research team, so that we expanded spatially. In total, we have gained about 150m² of laboratory space. This has further improved our research and development capabilities and increased our order processing capacity. We also have better spatial separation of thematic work areas, which means that the Dynamic42- BioChip production line and Dynamic42-BioChip quality control are now spatially separated from the cell culture and biochemical wet areas.
Growth driver organ-on-chip market
As a young company that develops customer-specific, biochip-based organ models, we benefit from the rapidly growing organ-on-chip market. In the coming years, we want to continue to grow and acquire new major customers. Our goal is to double the size of the company in the next two years and to significantly expand our market share in the target markets. Furthermore, the consolidation of the cooperation with renowned pharmaceutical companies as well as the expansion of the Dynamic42 platform technology are in the focus of our work.
With the continuous support of international research projects, we also continue to contribute to the improvement of studies on infectious diseases and drug testing. Not least to generate attention at all levels for the potential of our technology to replace animal testing.
We will build on the previous developments of our company and have set ourselves clear goals for 2022. We aim to expand our customer portfolio and achieve significant sales growth.
There are also some scientific publication and patenting of new developments in progress. There will also be a new Dynamic42 homepage soon.
However, our priority is to produce the Dynamic42-BioChips of the highest quality and to achieve the maximum customer satisfaction for our services. In addition to our growth ambitions and the technical development of our chip systems, our focus is therefore primarily on positioning Dynamic42 as a quality guarantor for organ-on-chip applications.
More interesting articles:
Summary of our work that established a human liver microphysiological model as an in vitro platform for the evaluation of drug-induced liver injury.Read More